The stock of Immix Biopharma Inc (IMMX) has seen a 15.31% increase in the past week, with a 40.94% gain in the past month, and a 36.93% flourish in the past quarter. The volatility ratio for the week is 7.03%, and the volatility levels for the past 30 days are at 4.78% for IMMX. The simple moving average for the last 20 days is 16.62% for IMMX stock, with a simple moving average of 28.85% for the last 200 days.
Is It Worth Investing in Immix Biopharma Inc (NASDAQ: IMMX) Right Now?
The 36-month beta value for IMMX is also noteworthy at 0.24. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMMX is 16.60M, and at present, short sellers hold a 1.33% of that float. The average trading volume of IMMX on May 23, 2025 was 54.47K shares.
IMMX) stock’s latest price update
The stock price of Immix Biopharma Inc (NASDAQ: IMMX) has surged by 15.31 when compared to previous closing price of 2.09, but the company has seen a 15.31% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety.
IMMX Trading at 31.65% from the 50-Day Moving Average
After a stumble in the market that brought IMMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.07% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 7.03%, as shares surge +37.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.85% upper at present.
During the last 5 trading sessions, IMMX rose by +15.31%, which changed the moving average for the period of 200-days by +10.55% in comparison to the 20-day moving average, which settled at $2.07. In addition, Immix Biopharma Inc saw 9.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMMX starting from Hsu Jason, who purchase 40,000 shares at the price of $2.19 back on Dec 23 ’24. After this action, Hsu Jason now owns 893,000 shares of Immix Biopharma Inc, valued at $87,680 using the latest closing price.
Hsu Jason, the Director of Immix Biopharma Inc, purchase 7,700 shares at $2.17 during a trade that took place back on Dec 20 ’24, which means that Hsu Jason is holding 853,000 shares at $16,678 based on the most recent closing price.
Stock Fundamentals for IMMX
The total capital return value is set at -2.06. Equity return is now at value -111.42, with -77.05 for asset returns.
Based on Immix Biopharma Inc (IMMX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -11.76.
Currently, EBITDA for the company is -21.54 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In summary, Immix Biopharma Inc (IMMX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
